KNWN - KNWN STOCK NEWS

Know Labs, Inc. (OTCQB: KNWN) has released a video update on its IRB-approved internal trial in Seattle, focusing on refining the algorithm for its Bio-RFID technology aimed at accurately measuring glucose levels non-invasively. Chief Product Officer Steve Kent discussed the extensive data collection process and the goal of achieving a production-ready algorithm for future clinical trials, which will be submitted for FDA approval. The company remains dedicated to launching the first FDA-cleared non-invasive blood glucose monitoring device.

Know Labs, Inc. (OTCQB: KNWN) filed a Form S-1 for a proposed offering of 3 million shares at $2.00 each. The company plans to uplist its shares to NYSE American, changing its ticker to "KNW" if approved. Proceeds from this offering will be allocated to research and development, sales, marketing, and operational expenses. The registration statement is pending approval from the SEC, and the securities cannot be sold until effective. Boustead Securities, LLC will underwrite the offering.

Know Labs, Inc. (OTCQB: KNWN) announced the appointment of two new senior executives: Steven Kent as Chief Product Officer and Peter Conley as Chief Financial Officer and SVP, Intellectual Property. These additions aim to strengthen the company's focus on obtaining FDA clearance for its non-invasive glucose monitoring technology. Conley brings over 34 years of finance experience, while Kent has expertise in medical technology and product development. The leadership team believes these changes are crucial for meeting significant milestones in 2022 and 2023.

Know Labs, Inc. (OTCQB: KNWN) has received two foundational patents to enhance its IP portfolio for its Bio-RFID™ technology, which focuses on non-invasive medical diagnostics. Patents 11,284,819 and 11,284,820 protect the creation and utilization of databases built from non-invasive sensor data. This positions Know Labs to dominate the field of non-invasive analyte diagnostics, significantly increasing its competitive advantage. The company is focused on its internal clinical trial for a non-invasive glucose monitoring device, aiming for FDA clearance.

Know Labs, Inc. (OTCQB: KNWN) is progressing towards launching the first FDA-cleared non-invasive glucose monitoring device using its proprietary Bio-RFID technology. A 200-person clinical trial is underway, showcasing high accuracy with a Mean Absolute Relative Difference (MARD) under 6%. Plans are in place to partner with a medical research institution for further validation. The company aims to expand its product applications and holds 30 patents with 48 pending. Know Labs also reported $4.2 million in revenue from NFTs and has strategic hires planned to support its goals for 2022.

Know Labs, Inc. (OTC-PINK: KNWN) has received approval from an independent Institutional Review Board for its internal clinical trial, marking a significant step toward its FDA pre-submission meeting. The trial aims to validate the Bio-RFID technology for non-invasive glucose monitoring, with 200 participants recruited in Seattle. Initial tests showed a 5.8% MARD in accuracy compared to FDA-cleared devices. Know Labs is set to begin the trial in the coming weeks, as it seeks to launch what could be the first non-invasive glucose monitor.

Know Labs, Inc. (OTCQB: KNWN) has announced its new subsidiary, AI Mind Inc. (AIM), has generated approximately $4.2 million from NFT sales, funding the development of AI technologies for its non-invasive glucose monitoring devices. AIM utilizes AI to identify blood glucose levels non-invasively, showing potential in generating further NFT revenue. The company sold over 1,000 NFTs, equating to more than 1,000 Ethereum. The revenue will support advancing their medical-grade glucose monitoring technology, with a clinical trial set to commence soon.

Know Labs, Inc. (OTCQB: KNWN) has announced independent test results confirming the efficacy of its Particle bulb, produced by its subsidiary Particle, Inc., in inactivating multiple SARS-CoV-2 variants. Testing by Texas Biomedical Research Institute showed a 95% reduction in virus levels after 5 hours, 99% after 6 hours, and 99.9% after 8 hours of exposure. Additionally, the Particle team is preparing for commercial production and exploring partnerships. CEO Phil Bosua believes it can play a vital role in addressing pandemics and controlling pathogens.

Know Labs, Inc. (OTCQB: KNWN) released a report highlighting the accuracy of its Bio-RFID™ technology in glucose monitoring. The technology achieved a mean absolute relative difference (MARD) of 5.3% to 6.7% compared to FDA-approved devices, demonstrating strong clinical performance. The advancements in miniaturization of the sensor are noted, transitioning from a large circuit board to a pocket-sized device. Know Labs aims to launch a non-invasive medical-grade glucose monitor and is seeking approval for human testing protocols to commence clinical studies.